HuyaBio International, which operates out of San Diego and Shanghai, China, has reported statistically significant Phase III results for HBI-8000 (tucidinostat) in combination with Bristol Myers Squibb's Opdivo (nivolumab) in advanced melanoma, a setting where existing checkpoint inhibitor combinations have left a substantial proportion of patients without durable benefit. The data position the combination as a potential first-line option and mark the first major Phase III readout for tucidinostat in a solid tumor indication outside its approved hematologic indications.
The HBI-8000-303 trial enrolled 404 patients with advanced melanoma across 15 countries in a randomized, placebo-controlled design. Patients receiving HBI-8000 plus nivolumab achieved a median progression-free survival of 11.7 months versus 7.4 months for nivolumab plus placebo — a 58% improvement that met the primary endpoint with statistical significance. Full data will be presented at a future medical meeting; further statistical analysis is described as ongoing.
Originally discovered by Shenzhen-based Chipscreen Bioscience and licensed to Huya Bioscience in 2007, HBI-8000 is a selective oral inhibitor of Class I and Class IIb histone deacetylases (HDACs), specifically HDAC1, 2, 3, and 10. HDAC inhibition promotes epigenetic reprogramming of the tumor microenvironment, and preclinical work has suggested it may enhance the immunostimulatory effects of PD-1 blockade — the mechanistic rationale for the combination. Nivolumab blocks PD-1, preventing tumor-mediated T-cell suppression. HBI-8000 already holds regulatory approval in China and Japan for lymphoma and has been prescribed to more than 90,000 patients, providing an established tolerability dataset that reduces one of the typical uncertainties at this stage.
The frontline melanoma space is crowded. BMS's Opdualag (nivolumab plus relatlimab) — a fixed-dose dual checkpoint combination targeting both PD-1 and LAG-3 — received FDA approval in 2022 and demonstrated a median PFS of 10.1 months versus 4.6 months for nivolumab monotherapy in the RELATIVITY-047 trial. The BMS Opdivo plus Yervoy (ipilimumab) combination remains a standard of care, though its toxicity profile limits use in some patients. Merck's Keytruda (pembrolizumab) monotherapy is also approved in the first-line setting.